Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Canopy Growth Corporation - Common Shares (NQ:CGC)

1.380 -0.080 (-5.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Canopy Growth Corporation - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Canopy Growth (CGC) Stock Is Falling Wednesday: What's Going On?
Shares of Canopy Growth are trading lower Wednesday, pulling back from a sharp rally on Monday. 
Via Benzinga
1 Major Reason Cannabis Stocks Surged This Week
President Trump's social media feed put the markets in a frenzy. 
Via The Motley Fool
Topics Cannabis ETFs Government
3 Best Marijuana Stocks to Buy in October
These three cannabis companies offer different ways to play an industry that's down by 80% from its peak, but showing signs of life. 
Via The Motley Fool
Topics Cannabis
Tilray, Canopy Growth: Cannabis Stocks Lose High Premarket After Surge Triggered By Trump's Post
Via Stocktwits
Topics Cannabis Government
Wall Street Lights Up as Cannabis Stocks Blaze Higher, Biotech Melts Down
U.S. markets kicked off the week quietly, but certain stocks were anything but dull. Cannabis names surged after a Trump-endorsed CBD video went viral, while biotech firm MoonLake was crushed by... 
Via Chartmill
Topics Cannabis
How Is The Market Feeling About Canopy Growth?
 
Via Benzinga
President Trump Lights Up Cannabis Stocks With Pro-CBD Truth Social Post
President Donald Trump posted a video on Truth Social on Sunday, promoting the potential health benefits of cannabis. Cannabis stocks lit up on Monday after Trump resurrected hopes for a change in... 
Via Benzinga
Topics Cannabis Government
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its... 
Via Benzinga
Tilray Brands Plunges Amidst Mounting FDA Approval Concerns and Regulatory Headwinds
New York, NY – September 25, 2025 – Tilray Brands Inc. (NASDAQ: TLRY) saw its stock tumble by a significant -5.21% on Thursday, September 25, 2025, as investor confidence continued to erode under the... 
Via MarketMinute
Topics Cannabis Economy
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results
 
Via Benzinga
Topics Stocks
Tuesday's pre-market session: top gainers and losers
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Stock Market Today: Dow, Nasdaq Futures Slide To Kick Off September On A Weak Note—Nio, Signet, Zscaler In Focus
U.S. stock futures dropped on Tuesday following Friday's negative moves. Futures of major benchmark indices were trading lower. 
Via Benzinga
Topics Stocks
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Nio, Signet Jewelers And 3 Stocks To Watch Heading Into Tuesday
U.S. stock futures lower on Tuesday. Nio, Hyperscale Data, Signet Jewelers, Canopy Growth, and Zscaler expected to report earnings. 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Which stocks are moving after the closing bell on Friday?
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
What's Going On With Tilray Stock Today?
Tilray shares rose ~5% after launching three EU-GMP medical cannabis strains in Germany and confirming renewed Nasdaq bid-price compliance. 
Via Benzinga
Topics Cannabis
Phibro Animal Health, Pure Storage, Snowflake, Build-A-Bear Workshop And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Verint Systems, Vital Energy And Other Big Stocks Moving Higher In Monday's Pre-Market Session
 
Via Benzinga
Cannabis ETFs Light Up As Trump Eyes Marijuana Reclassification
Cannabis stocks and ETFs skyrocketed after Trump hinted at reclassifying marijuana. Tilray surged 35% in 2 days. Other top performers included Trulieve, Tilray, Curaleaf, and Canopy Growth. This shift... 
Via Benzinga
Topics Cannabis ETFs Government
Tilray Surges 14% After Hours On Trump Cannabis Reclassification
Tilray stock surged 14.13% after hours as reports of a possible marijuana reclassification by Trump fueled investor optimism. 
Via Benzinga
Topics Cannabis Government
Trump Confirms Marijuana Reclassification Decision To Be Made In ‘Next Few Weeks’
Via Stocktwits
Topics Cannabis Government
While Investors Chase Monday's Tilray, Canopy And Aurora Rally, A Potential Federal Shift Could Redefine Cannabis Growth Fundamentals
Shares of major cannabis companies are trading higher Monday morning. The stocks are soaring following a WSJ report that President Trump is considering reclassifying marijuana as a less dangerous... 
Via Benzinga
Topics Cannabis Government
Monday's pre-market session: top gainers and losers
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Retail Bulls Pile Into Cannabis Stocks On Reports Trump May Reclassify Marijuana; Traders Eye Aurora Rally
Via Stocktwits
Topics Cannabis Government
Adult-Use Cannabis Boom Powers Canopy Growth Sales, But Wider Loss Hits Margins
Canopy Growth reported higher-than-expected Q1 revenue fueled by cannabis sales, but margins narrowed and earnings missed analyst expectations. 
Via Benzinga
Topics Cannabis Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.